Multicenter, prospective, randomized clinical trial to assess two different doses of anti-human-T-lymphocyte immune serum preparation derived from rabbit in GVHD profilaxis in pediatric population with haematologic malignancies riceiving non allogenic stem cell transplantation.

INTERVENTION: Trade Name: ATG‐Fresenius Pharmaceutical Form: Solution for infusion INN or Proposed INN: Antithymocyte immunoglobulin (rabbit) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: graft versus host disease profilactic use ; MedDRA version: 9.1 Level: LLT Classification code 10018653 Term: Graft‐versus‐host disease PRIMARY OUTCOME: Main Objective: to evaluate different ATG doses on acute GVHD incidence and severity. Primary end point(s): cumulative incidence of acute GVHD (grade II‐IV) Secondary Objective: to compare incidence of chronic GVHD in two treatment groups. INCLUSION CRITERIA: patients affected with LLA, LMA, LNH, LMC Ph+ RC, AREB, AREB‐t, LMMC; age 0‐19 years; written inform consensus; ... Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range